Drugs / Recombinant Human Albumin
Recombinant Human Albumin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04641364 | Jun 2019 → May 2020 | — | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06411743 | Sep 2021 → Aug 2022 | — | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06911554 | Jun 2023 → Sep 2024 | — | Tonghua Anrate Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Albumin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06911554 ↗ |
| Known as | recombinant Human Serum Albumin | “Subjects received recombinant Human Serum Albumin, 1.25g, 5g, 10g, 20g, 30 g for the single dose study.” NCT04641364 ↗ |
| Known as | rHA | “The Phase II clinical study aimed to evaluate the dose-response relationship, safety, and immunogenicity of recombinant human albumin(rHA) injection for the treatment of...” NCT06411743 ↗1“This study was a Phase III multicenter, blinded, and positive active-controlled clinical study to evaluate the efficacy, safety, and immunogenicity of recombinant human...” NCT06911554 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Recombinant Human Albumin” NCT06411743 ↗ |
| Route | Intravenous | “single dose or multiple doses of intravenous infusion” NCT04641364 ↗ |